Active targeting of our hybrid gold nanoparticles on HER2-overexpressing breast cancer cells, in patient-derived xenografts of HER2-overexpressing breast cancer, increased gold delivery to cancer cells. This evidence concerns the gene ERBB2 and breast cancer.